Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328374 | 1.00 | FFAR3 (0.32) | FFAR3ALDH1A1 | |
| SCHEMBL1254874 | 1.00 | FFAR3 (0.32) | FFAR3ALDH1A1 | |
| SCHEMBL27202100 | 0.90 | — | — | |
| SCHEMBL2572504 | 0.86 | ALDH1A1 (0.35) | FFAR3ALDH1A1 | |
| SCHEMBL26940408 | 0.84 | — | — | |
| SCHEMBL29108746 | 0.83 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL16409142 | 0.83 | — | — | |
| SCHEMBL26942120 | 0.80 | — | — | |
| SCHEMBL16407741 | 0.78 | CYP1A2 (0.30) | — | |
| SCHEMBL19388256 | 0.78 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | FFAR3 981/4885ALDH1A1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.